Acquisition of Exclusive Manufacturing and Marketing Rights for DOTATOC

Acquisition of Exclusive Manufacturing and Marketing Rights for DOTATOC 

    --  In-licensing of superior DOTA-Tyr(3)-octreotide
    --  Pharmaceutical developmentfor treatment of NETs
    --  Excellent pharmacokinetic properties

GARCHING, Germany, Sept. 18, 2013 /CNW/ - ITM Isotope Technologies Munich AG 
(ITM) today announced that it has entered into an exclusive licensing 
agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development 
and commercialization of radiolabeled DOTA-conjugated somatostatin analogue 
DOTA-[Tyr3]-octreotide (DOTATOC known as Edotreotide) for human oncology 
therapeutic use. Radiolabeled DOTATOC is a superior agent for safe and highly 
effective radionuclide therapy of somatostatin receptor positive tumors which 
offers excellent pharmacokinetic properties and highest affinity to 
somatostatin receptor subtypes 2 and 5.

Scope of license agreement

The sublicense granted by Progenics Pharmaceuticals Inc. covers exclusive 
worldwide manufacturing and marketing rights of DOTATOC and certain 
radiolabeled DOTATOC for human oncology therapeutic use except the countries 
Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, 
Lebanon, Oman, Qatar, Romania, Saudi Arabia, Syria, Turkey and United Arab 
Emirates. Further terms of the agreement were not disclosed.

Pharmaceutical development

ITM affiliate ITG Isotope Technologies Garching GmbH will develop radiolabeled 
DOTATOC for treatment of metastatic neuroendocrine tumors. In addition, 
DOTATOC as precursor is now available and will be distributed in GMP quality 
in cooperation with a leading supplier of advanced chemicals for nuclear 


DOTATOC or Edotreotide is a superior synthetic somatostatin analog which binds 
perfectly to somatostatin receptors predominantly overexpressed in 
neuroendocrine tumors (NETs). NETs are rare kind of tumors which arise from 
neuroendocrine cells and may occur in different parts of the body.

DOTA-chelated peptide Edotreotide exhibits excellent pharmacokinetic 
properties and can be efficiently radiolabeled with medical radionuclides. Its 
excellent therapeutic properties have been successfully started in various 
clinical trials.

About ITM Isotope Technologies Munich AG

Theitm Group is the leading company for the development, production and 
worldwide distribution of highly effective radionuclides for diagnosis and 
therapy as well as radionuclide-based medical devices. Its commitment to 
shaping the future of theranostics is built on robust platform technologies 
and innovative new generation radioisotopes which assure safety, performance 
and security of supply!

ITM Isotope Technologies Munich AG

Aufsichtsratsvorsitzender - Udo J. Vetter, Vorstandsvorsitzender - Steffen 
Schuster, Sitz der Gesellschaft - Lichtenbergstr. 1, 85748 Garching - HG 
München - HRB 154944

SOURCE  ITM Isotope Technologies Munich AG 
Christopher Morin Manager Marketing & Corporate Communications Phone: 
Steffen Schuster CEO Phone: +49-89-289-13970 
To view this news release in HTML formatting, please use the following URL: 
CO: ITM Isotope Technologies Munich AG
-0- Sep/18/2013 15:21 GMT
Press spacebar to pause and continue. Press esc to stop.